Castle Biosciences (CSTL) Stock Analysis & AI Equity Report
Castle Biosciences (CSTL) overview
Castle Biosciences (CSTL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 344m and operating profit of USD -42.8m; the year-end share price was 38.90 USD and market capitalisation was USD 1,155m. Castle Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Castle Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Castle Biosciences
Castle Biosciences is a molecular diagnostics company offering tests to aid clinicians in diagnosing and treating dermatologic cancers, Barrett’s esophagus, uveal melanoma, and atopic dermatitis. Its portfolio includes tissue-based tests that characterize patient biology and provide information relevant to diagnosis, risk assessment, treatment, and patient management. The company serves clinicians in dermatology, gastroenterology, and ophthalmology.
Generate the Castle Biosciences report
Castle Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Castle Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Castle Biosciences
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.